IL291571B2 - Cx3cr1-binding polypeptides - Google Patents

Cx3cr1-binding polypeptides

Info

Publication number
IL291571B2
IL291571B2 IL291571A IL29157122A IL291571B2 IL 291571 B2 IL291571 B2 IL 291571B2 IL 291571 A IL291571 A IL 291571A IL 29157122 A IL29157122 A IL 29157122A IL 291571 B2 IL291571 B2 IL 291571B2
Authority
IL
Israel
Prior art keywords
seq
domain
polypeptide according
single variable
immunoglobulin single
Prior art date
Application number
IL291571A
Other languages
English (en)
Hebrew (he)
Other versions
IL291571B1 (en
IL291571A (en
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL291571(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of IL291571A publication Critical patent/IL291571A/en
Publication of IL291571B1 publication Critical patent/IL291571B1/en
Publication of IL291571B2 publication Critical patent/IL291571B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
IL291571A 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides IL291571B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603622P 2012-02-27 2012-02-27
PCT/US2013/027580 WO2013130381A1 (en) 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides

Publications (3)

Publication Number Publication Date
IL291571A IL291571A (en) 2022-05-01
IL291571B1 IL291571B1 (en) 2024-04-01
IL291571B2 true IL291571B2 (en) 2024-08-01

Family

ID=47884535

Family Applications (3)

Application Number Title Priority Date Filing Date
IL291571A IL291571B2 (en) 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides
IL311502A IL311502A (en) 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides
IL234018A IL234018B2 (en) 2012-02-27 2014-08-07 cx3cr1 binding polypeptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL311502A IL311502A (en) 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides
IL234018A IL234018B2 (en) 2012-02-27 2014-08-07 cx3cr1 binding polypeptides

Country Status (27)

Country Link
US (6) US9035029B2 (enExample)
EP (2) EP4050027A3 (enExample)
JP (1) JP6101715B2 (enExample)
KR (1) KR102008136B1 (enExample)
CN (3) CN104245735B (enExample)
AP (1) AP2014007791A0 (enExample)
AR (1) AR090158A1 (enExample)
AU (1) AU2013226340B2 (enExample)
CA (1) CA2862182A1 (enExample)
CL (1) CL2014002072A1 (enExample)
EA (1) EA028183B1 (enExample)
EC (1) ECSP14020402A (enExample)
GE (1) GEP201706773B (enExample)
IL (3) IL291571B2 (enExample)
IN (1) IN2014DN05756A (enExample)
MD (1) MD4548C1 (enExample)
MX (1) MX349192B (enExample)
NZ (1) NZ627260A (enExample)
PE (1) PE20141859A1 (enExample)
PH (2) PH12014501912B1 (enExample)
SG (1) SG11201405283SA (enExample)
TN (1) TN2014000360A1 (enExample)
TW (1) TWI598361B (enExample)
UA (1) UA115781C2 (enExample)
UY (1) UY34644A (enExample)
WO (1) WO2013130381A1 (enExample)
ZA (3) ZA201405021B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
KR102008136B1 (ko) 2012-02-27 2019-08-08 베링거 인겔하임 인터내셔날 게엠베하 Ｃｘ3ｃｒ1-결합 폴리펩타이드
EP3035970A1 (en) * 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
EP3325512B1 (en) 2015-07-23 2023-09-06 Inhibrx, Inc. Multivalent and multispecific gitr-binding fusion proteins
SG11201805422WA (en) 2016-01-11 2018-07-30 Inhibrx Inc Multivalent and multispecific ox40-binding fusion proteins
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR20230041739A (ko) * 2016-03-08 2023-03-24 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
JP7112735B2 (ja) 2016-11-29 2022-08-04 国立研究開発法人国立精神・神経医療研究センター 進行型免疫性脱髄疾患の予防、発症抑制又は治療剤
WO2018134815A2 (en) * 2017-01-17 2018-07-26 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
IL317013A (en) 2017-09-08 2025-01-01 Takeda Pharmaceuticals Co Binding proteins are activated under limited conditions
AR114552A1 (es) 2018-08-13 2020-09-16 Inhibrx Inc Polipéptidos de unión a ox40 y sus usos
JP2022524338A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
CN110675421B (zh) * 2019-08-30 2022-03-15 电子科技大学 基于少量标注框的深度图像协同分割方法
WO2022165434A2 (en) * 2021-02-01 2022-08-04 The General Hospital Corporation Fc-enhanced antibodies for prevention and treatment of ebola virus infection
TW202246334A (zh) * 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
CA3262048A1 (en) 2022-07-18 2024-01-25 Sanofi Sa Cx3cr1-binding compounds, methods and uses thereof
IL321045A (en) 2022-12-22 2025-07-01 Chiome Bioscience Inc Anti-human CX3CR1 antibody
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
AU2000273378A1 (en) * 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
EP1278767A4 (en) 2000-04-12 2003-11-12 Principia Pharmaceutical Corp ALBUMIN FUSED PROTEINS
US20020192212A1 (en) 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20060160076A1 (en) 2002-06-10 2006-07-20 Meatabolex, Inc. Methods of treating and diagnosing diabetes with cx3cr1 modulators
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
CN100343304C (zh) 2002-12-31 2007-10-17 尼克塔治疗亚拉巴马公司 水解稳定的马来酰亚胺封端的聚合物
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
WO2005103684A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
RU2007117752A (ru) 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
WO2006046739A1 (ja) 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
JP2009504659A (ja) 2005-08-08 2009-02-05 オンコノン・リミテッド・ライアビリティ・カンパニー 抗体組成物、腫瘍性疾患の処置方法、および受胎能の調節方法
CA2618482C (en) * 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US20100113339A1 (en) * 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
CN101611056A (zh) 2006-12-05 2009-12-23 埃博灵克斯股份有限公司 能够结合于血清蛋白的肽
CN101965362A (zh) 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
PT2285408T (pt) 2008-06-05 2019-02-01 Ablynx Nv Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais
WO2010070394A1 (en) 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
WO2011044377A2 (en) 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
EP2486056A1 (en) * 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2012078633A2 (en) * 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
KR102008136B1 (ko) 2012-02-27 2019-08-08 베링거 인겔하임 인터내셔날 게엠베하 Ｃｘ3ｃｒ1-결합 폴리펩타이드
EP3035970A1 (en) 2013-08-21 2016-06-29 Boehringer Ingelheim International GmbH Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease

Also Published As

Publication number Publication date
WO2013130381A1 (en) 2013-09-06
US20180030141A1 (en) 2018-02-01
CN108610421B (zh) 2022-08-19
PH12014501912A1 (en) 2014-11-24
UA115781C2 (uk) 2017-12-26
PH12014501912B1 (en) 2023-01-18
EP4050027A2 (en) 2022-08-31
CN104245735B (zh) 2018-02-23
US20190322753A1 (en) 2019-10-24
MD4548B1 (ro) 2018-01-31
US9458235B2 (en) 2016-10-04
US20230046772A1 (en) 2023-02-16
PE20141859A1 (es) 2014-12-17
TW201348256A (zh) 2013-12-01
NZ627260A (en) 2015-10-30
JP2015509368A (ja) 2015-03-30
MX349192B (es) 2017-07-18
KR102008136B1 (ko) 2019-08-08
IL234018A0 (en) 2014-09-30
US20160355595A1 (en) 2016-12-08
IL291571B1 (en) 2024-04-01
CA2862182A1 (en) 2013-09-06
HK1205154A1 (en) 2015-12-11
EA201400964A1 (ru) 2015-02-27
US11384151B2 (en) 2022-07-12
US12221487B2 (en) 2025-02-11
KR20140130685A (ko) 2014-11-11
GEP201706773B (en) 2017-11-27
US9783612B2 (en) 2017-10-10
US20130224224A1 (en) 2013-08-29
ZA202308846B (en) 2025-03-26
BR112014021080A2 (pt) 2017-07-04
EA028183B1 (ru) 2017-10-31
ECSP14020402A (es) 2015-11-30
PH12021553014A1 (en) 2022-09-05
MD20140104A2 (ro) 2015-02-28
EP4050027A3 (en) 2022-11-30
CN108610421A (zh) 2018-10-02
SG11201405283SA (en) 2014-10-30
ZA201405021B (en) 2024-09-25
MX2014009864A (es) 2014-10-24
AU2013226340B2 (en) 2017-06-22
MD4548C1 (ro) 2018-08-31
CN104245735A (zh) 2014-12-24
CN115925938A (zh) 2023-04-07
CL2014002072A1 (es) 2015-01-23
AR090158A1 (es) 2014-10-22
IN2014DN05756A (enExample) 2015-04-10
IL234018B1 (en) 2023-01-01
US20240026013A2 (en) 2024-01-25
IL311502A (en) 2024-05-01
TWI598361B (zh) 2017-09-11
UY34644A (es) 2013-09-02
US9035029B2 (en) 2015-05-19
EP2820046A1 (en) 2015-01-07
ZA202308845B (en) 2025-03-26
EP2820046B1 (en) 2022-06-15
US20150239971A1 (en) 2015-08-27
AU2013226340A1 (en) 2014-07-31
US10385134B2 (en) 2019-08-20
AP2014007791A0 (en) 2014-07-31
TN2014000360A1 (en) 2015-12-21
JP6101715B2 (ja) 2017-03-22
IL234018B2 (en) 2023-05-01
IL291571A (en) 2022-05-01
US20240279349A2 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
IL291571B2 (en) Cx3cr1-binding polypeptides
US11485778B2 (en) Immunoglobulin variable domains
CN110191896B (zh) 改进的血清白蛋白结合物
ES2729320T3 (es) Inmunización genética para producir inmunoglobulinas contra antígenos asociados a células tales como P2X7, CXCR7 o CXCR4
IL316293A (en) Improved serum albumin binders
ES2924282T3 (es) Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas
JP2018537421A5 (enExample)
CN108290943A (zh) 改进的血清白蛋白结合免疫球蛋白可变结构域
JP2019503990A (ja) 改良された血清アルブミン結合剤
JP7189211B2 (ja) 血清中のタンパク質の半減期を増加させるための組成物及び方法
CA3120102A1 (en) Engineered cd25 polypeptides and uses thereof
CN117820479A (zh) 抗il-17a的新型纳米抗体
CN117843803B (zh) 串联单域抗体及其在疾病治疗中的应用
CN117820477B (zh) 抗il-17a单域抗体串联体及其应用
CN120659804A (zh) 多价蛋白质及筛选方法
CN117843777A (zh) 用于炎性疾病治疗的新型纳米抗体及其产品和方法
Ebrahimi et al. Nanobody as a New Generation of Functional Proteins: Nanobody as a new functional domains
RU2774823C2 (ru) Усовершенствованные агенты, связывающие tnf
RU2025103398A (ru) Cx3cr1-связывающие соединения, пути их применения и связанные с ними способы
RU2809788C2 (ru) Улучшенные вариабельные домены иммуноглобулина
WO2024168801A1 (zh) 抗TfR1的单域抗体及其用途
CN117843779A (zh) 抗体、核酸、药物制剂和炎性疾病治疗方法
CN117843778A (zh) 针对白介素家族成员的新型纳米抗体及其产品和应用
HK40035363A (en) Immunoglobulin variable domains